Cargando…

Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma

Medulloblastoma is the most common malignant childhood brain tumor, and 5-year overall survival rates are as low as 40% depending on molecular subtype, with new therapies critically important. As radiotherapy and chemotherapy act through the induction of DNA damage, the sensitization of cancer cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buck, Jessica, Dyer, Patrick J. C., Hii, Hilary, Carline, Brooke, Kuchibhotla, Mani, Byrne, Jacob, Howlett, Meegan, Whitehouse, Jacqueline, Ebert, Martin A., McDonald, Kerrie L., Gottardo, Nicholas G., Endersby, Raelene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Molecular Biosciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116896/ https://www.ncbi.nlm.nih.gov/pubmed/33996894 http://dx.doi.org/10.3389/fmolb.2021.633344

Ejemplares similares

RONC-07. Fractionated radiotherapy is required to accurately mimic neurostructural late effects in preclinical models
por: Whitehouse, Jacqueline, et al.
Publicado: (2022)

BIOL-12. ENHANCING IMMUNE-MEDIATED TUMOR CONTROL IN MURINE MODELS OF GROUP 3 MEDULLOBLASTOMA
por: Abbas, Zahra, et al.
Publicado: (2023)

RONC-02. MEASURING THE EFFECT OF CLINICALLY-RELEVANT RADIOTHERAPY PROTOCOLS ON THE JUVENILE MOUSE BRAIN
por: Buck, Jessica, et al.
Publicado: (2020)

Assessment of Cannabidiol and Δ9-Tetrahydrocannabiol in Mouse Models of Medulloblastoma and Ependymoma
por: Andradas, Clara, et al.
Publicado: (2021)

A Novel Orthotopic Patient-Derived Xenograft Model of Radiation-Induced Glioma Following Medulloblastoma
por: Whitehouse, Jacqueline P., et al.
Publicado: (2020)

Conventional Therapies Deplete Brain-Infiltrating Adaptive Immune Cells in a Mouse Model of Group 3 Medulloblastoma Implicating Myeloid Cells as Favorable Immunotherapy Targets
por: Abbas, Zahra, et al.
Publicado: (2022)

DIPG-50. A NOVEL ORTHOTOPIC PATIENT-DERIVED XENOGRAFT MODEL OF RADIATION-INDUCED GLIOMA
por: Whitehouse, Jacqueline, et al.
Publicado: (2020)

Defining the molecular features of radiation-induced glioma: A systematic review and meta-analysis
por: Whitehouse, Jacqueline P, et al.
Publicado: (2021)

A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors
por: Endersby, Raelene, et al.
Publicado: (2018)

MOMC-5. Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma
por: Genovesi, Laura, et al.
Publicado: (2021)

Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma
por: Genovesi, Laura A., et al.
Publicado: (2021)

A novel technique of serial biopsy in mouse brain tumour models
por: Rogers, Sasha, et al.
Publicado: (2017)

Chemotherapy-induced peripheral neuropathy in children and adolescent cancer patients
por: Tay, Nicolette, et al.
Publicado: (2022)

In vivo loss of tumorigenicity in a patient-derived orthotopic xenograft mouse model of ependymoma
por: Whitehouse, Jacqueline P., et al.
Publicado: (2023)

Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma
por: Jue, Toni Rose, et al.
Publicado: (2017)

Editorial: Bench to bedside: translating pre-clinical research into clinical trials for childhood brain tumors
por: Endersby, Raelene, et al.
Publicado: (2023)

MDB-36. SONIDEGIB, GANT61, AND VELIPARIB TREATMENT BOTH ALONE AND IN COMBINATION INCREASES RADIATION SENSITIVITY IN PEDIATRIC SONIC HEDGEHOG MEDULLOBLASTOMA
por: Price, Laura, et al.
Publicado: (2023)

The Role of Cannabinoids as Anticancer Agents in Pediatric Oncology
por: Andradas, Clara, et al.
Publicado: (2021)

Systematic analysis of MCM3 in pediatric medulloblastoma via multi-omics analysis
por: Cao, Liangliang, et al.
Publicado: (2022)

Corrigendum: Systematic analysis of MCM3 in pediatric medulloblastoma via multi-omics analysis
por: Cao, Liangliang, et al.
Publicado: (2022)

Profile of veliparib and its potential in the treatment of solid tumors
por: Wagner, Lars M
Publicado: (2015)

A chemical screen for medulloblastoma identifies quercetin as a putative radiosensitizer
por: Lagerweij, Tonny, et al.
Publicado: (2016)

Limitations of radiosensitization by direct telomerase inhibition to treat high-risk medulloblastoma
por: Sengupta, Satarupa, et al.
Publicado: (2023)

Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group
por: Gottardo, Nicholas G., et al.
Publicado: (2013)

Clinical evidence for synergy between immunotherapy and radiotherapy (SITAR)
por: Gill, Suki, et al.
Publicado: (2022)

NRP1 inhibition modulates radiosensitivity of medulloblastoma by targeting cancer stem cells
por: Douyère, Manon, et al.
Publicado: (2022)

Effect of the PARP inhibitor veliparib on germ cell tumor cell lines
por: Schmidtova, Silvia, et al.
Publicado: (2022)

A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study
por: Sim, Hao-Wen, et al.
Publicado: (2021)

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors
por: Bartelink, Imke H., et al.
Publicado: (2017)

Blocking PARP activity with the inhibitor veliparib enhances radiotherapy sensitivity in endometrial carcinoma
por: Wang, Jing, et al.
Publicado: (2022)

Synthesis of Veliparib Prodrugs and Determination of Drug-Release-Dependent PARP-1 Inhibition
por: Borgini, Matteo, et al.
Publicado: (2023)

Arsenic Trioxide exerts cytotoxic and radiosensitizing effects in pediatric Medulloblastoma cell lines of SHH Subgroup
por: dos Santos Klinger, Paulo Henrique, et al.
Publicado: (2020)

Cryptic developmental events determine medulloblastoma radiosensitivity and cellular heterogeneity without altering transcriptomic profile
por: Malawsky, Daniel Shiloh, et al.
Publicado: (2021)

Sphingosine Kinase 1 Signaling in Breast Cancer: A Potential Target to Tackle Breast Cancer Stem Cells
por: Hii, Ling-Wei, et al.
Publicado: (2021)

Combination of Radiosensitivity Gene Signature and PD-L1 Status Predicts Clinical Outcome of Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma: A Study Based on The Cancer Genome Atlas Dataset
por: Dai, Dongjun, et al.
Publicado: (2021)

Knockdown of EphB1 receptor decreases medulloblastoma cell growth and migration and increases cellular radiosensitization
por: Bhatia, Shilpa, et al.
Publicado: (2015)

Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma
por: Gabrielson, Andrew, et al.
Publicado: (2015)

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer
por: Stringer-Reasor, Erica M., et al.
Publicado: (2021)

Preclinical Models of Craniospinal Irradiation for Medulloblastoma
por: Stripay, Jennifer L., et al.
Publicado: (2020)

Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer
por: Nishio, Shin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7iqn3god9605vkgigc0j10rgib